We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
RANDOX LABORATORIES

Download Mobile App




Events

17 Jun 2026 - 19 Jun 2026
08 Jul 2026 - 10 Jul 2026

Microarray Chip Rapidly Detects Dengue Fever

By LabMedica International staff writers
Posted on 21 Jul 2014
A chip has been developed that allows for the detection of the ribonucleic acid (RNA) strand of the virus that causes dengue fever, now endemic in 110 countries. More...


The chip allows analysis of the complementary strand of DNA (cDNA) obtained from the dengue fever virus being carried by the infected patient and the cDNA is covalently linked to a slide or substrate that can be a glass or paper.

Scientists at the Center for Research and Advanced Studies (Cinvestav; Mexico City, Mexico) used probes marked with fluorescent elements, called fluorochromes that can distinguish in the chip different colors according to the serotype of dengue fever the patient is carrying. Additionally, the cDNA microarray can display more than one color if the patient carries two serotypes.

The scientists said that knowing the precise serotype of dengue fever virus the patient is carrying, the progression of the disease would stop and an optimal follow up of the treatment would be held. There are five strains of the virus, called serotypes, of which the first four are referred to as DENV-1, DENV-2, DENV-3 and DENV-4 and the distinctions between the serotypes is based on their antigenicity. If a painkiller or an antihistamine are prescribed to the patient infected by the dengue virus, such drugs could cause a thinning of the blood vessels walls, thus triggering hemorrhagic fever.

Maria de Lourdes Muñoz Moreno, PhD, a senior scientist, at the Department of Genetics and Molecular Biology at Cinvestav, said, “When it comes to a second infection with another serotype, the antibodies that protect the body from dengue fever in the first infection, could now adhere to the virus of a new serotype, causing the cells to be more easily infected.” The group at Cinvestav is working to achieve a microarray that differentiates dengue fever from Chikungunya, a viral disease recently reported in Latin America that is transmitted in a dengue-like manner, causing an acute febrile phase lasting two to five days.

Related Links:

Center for Research and Advanced Studies



Gold Member
STI Test
Vivalytic MG, MH, UP/UU
Online QC Software
Acusera 24•7
Immunofluorescence Analyzer
IFA System
Chromogenic Culture System
InTray™ COLOREX™ ECC
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Researchers use a novel immobilized liposome-bound gel beads method to measure CEC levels and their association with cardiovascular risks (Photo courtesy of Institute of Science Tokyo)

Simple Blood-Based Cholesterol Efflux Assay Identifies High-Risk Coronary Plaque Features

Unstable coronary plaques are difficult to identify before they trigger acute cardiovascular events. Standard high-density lipoprotein (HDL) measurements do not always capture how well HDL particles function... Read more

Pathology

view channel
Image: Overview of the uncertainty-aware lensfree computational pathology platform for automated HER2 assessment. A compact lensfree holographic imaging system captures diffraction patterns from immunohistochemically stained breast tissue samples, which are computationally reconstructed and analyzed using deep neural networks with Bayesian uncertainty quantification. (Photo courtesy of Ozcan Lab, UCLA)

Uncertainty-Aware AI Platform Supports Automated HER2 Assessment in Breast Cancer

Accurate assessment of human epidermal growth factor receptor 2 (HER2) is critical for breast cancer diagnosis and treatment selection, yet scoring variability and infrastructure requirements can complicate... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.